MPI DTPA KIT - CHELATE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MPI DTPA KIT - CHELATE is an injectable diagnostic radiopharmaceutical kit approved in 1976 for chelation and imaging purposes. The product is a diagnostic agent used in nuclear medicine imaging procedures. It is administered via injection to enable diagnostic visualization in patient populations requiring chelation assessment.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; team focus is likely on manufacturing efficiency and regulatory maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MPI DTPA KIT - CHELATE positions you in GE HealthCare's engineering, manufacturing, and technical operations functions rather than commercial or R&D roles. The 916 linked jobs reflect a mature operational footprint focused on maintaining a legacy diagnostic platform.
Data ManagerDualer Student (w/m/d) Betriebswirtschaftslehre
Worked on MPI DTPA KIT - CHELATE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.